Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986460 in Metastatic Castration-resistant Prostate Cancer
NCT06067841Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2023
- Primary completion
- Aug 2029
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of BMS-986460 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Bristol Myers Squibb. Primary endpoints: Adverse Events at 112 weeks, Serious Adverse Events at 112 weeks and 3 more. Started Oct 2023; status: recruiting.
02
Drugs
BMS-986460
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06067841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06067841.